Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

This procedure can only be done as part of a research study. This is because there is not enough evidence to be sure how well it works. Your healthcare professional should talk to you about the ...

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document (FAD) on tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'. The ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. The minutes of each evaluation committee meeting, which include the names of ...

Interstitial cystitis, also known as bladder pain syndrome, is a chronic inflammatory condition of the bladder. The main symptoms are pelvic pain, urinary urgency, urinary frequency and nocturia.